Viewing Study NCT04589650

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:16 PM
Ignite Modification Date: 2026-02-23 @ 8:08 PM
Study NCT ID: NCT04589650
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-17
First Post: 2020-10-14
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None PIK3CA-related Overgrowth Spectrum (PROS) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PIK3CA-related overgrowth spectrum (PROS) View
None Alpelisib View
None BYL719 View
None Adult View
None Pediatric View
None Phase II View